Boehringer Ingelheim (Canada) Ltd. has announced that Health Canada has approved Giotrif (afatinib) tablets for oral use, as a new treatment for Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor naïve patients with metastatic (including cytologically proven pleural effusion) adenocarcinoma of the lung with activating EGFR mutation(s). Approximately 20 per cent of all lung cancer cases have reported EGFR mutations.

For more details, go to: http://www.boehringer-ingelheim.ca/en/news/press_releases/20131/07nov20131.html